Patients' disease has progressed after prior chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib or erlotinib treatment. Due to the study inclusion criteria a high proportion of patients that may have mutated EGF receptors in their tumours were included.